Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
December 09 2021 - 07:00AM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today presented positive data at the ESMO
Immuno-Oncology Congress 2021 (ESMO I-O) that further demonstrate
that Achilles’ VELOS™ Process 2 manufacturing increases clonal
neoantigen-reactive T cell (cNeT) doses by more than 10-fold over
Process 1 at GMP scale and maintains a highly potent
polyclonal phenotype. These data add to the pilot scale
proof-of-concept study recently reported at the 2021 Society for
Immunotherapy of Cancer (SITC) Annual Meeting.
“We are extremely pleased to have demonstrated
the ability to generate a significant boost in cNeT dose over
Process 1 in clinical-scale runs and to have successfully completed
the technology transfer of Process 2 into clinical manufacture,”
said Dr Ed Samuel, SVP Technical
Operations of Achilles. “These Process 2 GMP data validate
our previously reported R&D data and confirm retention of
critical phenotypic characteristics and the ability to identify the
active drug component of our products without adding to end-to-end
manufacturing time. We anticipate dosing patients with high-dose
Process 2 cNeT in the first half of 2022, with 6-week clinical and
translational science data available in the second half 2022.”
Key highlights from the presentation entitled
“Achilles VELOS Process 2 generates a >10-fold improvement in
cNeT dose over Process 1 with a highly potent polyclonal phenotype
and has been successfully validated at GMP scale for clinical use
in solid cancer,” include:
- Reporting that GMP validation of
VELOS Process 2 has successfully been completed and transferred
into clinical manufacture in Achilles’ ongoing Phase I/IIa CHIRON
and THETIS clinical trials
- Showing that VELOS Process 2
generates a cell product that retains both CD4+ and CD8+ T cell
subsets and maintains polyclonal cNeT reactivity with a favorable
cell fitness phenotype
- Demonstrating the quantification of
the active cNeT drug component with Achilles’ proprietary potency
assay which further underlines the strength of the Achilles
platform
Achilles ESMO I-O 2021 Poster
Details
Title: Achilles VELOS Process 2 generates a
>10-fold improvement in cNeT dose over Process 1 with a highly
potent polyclonal phenotype and has been successfully validated at
GMP scale for clinical use in solid cancerAuthors:
Evi Rologi, et al.
Date &
Time: Poster available online from Thursday, December
9, 2021, at 12:30 PM CET / 11:30 AM UK / 6:30AM
ETPoster ID: 58P
The poster presentation is available in the
Events & Presentations section of the Company website.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
unresectable locally advanced and metastatic non-small cell lung
cancer (NSCLC) and the THETIS trial in patients with recurrent or
metastatic melanoma. Achilles uses DNA sequencing data from each
patient, together with its proprietary PELEUS™ bioinformatics
platform, to identify clonal neoantigens specific to that patient,
and then develop precision T cell-based product candidates
specifically targeting those clonal neoantigens.
Forward-Looking StatementsThis
press release contains express or implied forward-looking
statements that are based on our management's belief and
assumptions and on information currently available to our
management. Although we believe that the expectations reflected in
these forward-looking statements are reasonable, these statements
relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Further information:
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Mar 2023 to Mar 2024